Cargando…
Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma
BACKGROUND: Temozolomide (TMZ) chemotherapy is a current standard of care for glioblastoma (GBM), however it has only extended overall survival by a few months. Because it also modulates the immune system, both beneficially and negatively, understanding how TMZ interacts with immunotherapeutics is i...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BMJ Publishing Group
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252967/ https://www.ncbi.nlm.nih.gov/pubmed/32457126 http://dx.doi.org/10.1136/jitc-2019-000345 |